Edition:
India

Arsanis Inc (ASNS.OQ)

ASNS.OQ on NASDAQ Stock Exchange Global Market

2.98USD
18 Jul 2018
Change (% chg)

$-0.12 (-3.87%)
Prev Close
$3.10
Open
$3.09
Day's High
$3.09
Day's Low
$2.94
Volume
26,524
Avg. Vol
22,155
52-wk High
$27.83
52-wk Low
$2.94

Latest Key Developments (Source: Significant Developments)

Arsanis Says Phase 2 Clinical Trial Of ASN100 Unlikely To Meet Primary Efficacy Endpoint
Thursday, 28 Jun 2018 

June 28 (Reuters) - Arsanis Inc ::ARSANIS PROVIDES UPDATE FOLLOWING COMPLETION OF PLANNED INTERIM ANALYSIS OF PHASE 2 CLINICAL TRIAL OF ASN100.TRIAL UNLIKELY TO MEET PRIMARY EFFICACY ENDPOINT; ARSANIS TO CEASE TRIAL ENROLLMENT AND EVALUATE COMPLETE CLINICAL TRIAL DATASET.ARSANIS TO CONTINUE FOCUS ON DEVELOPMENT OF ASN500 FOR PREVENTION OF RSV INFECTION.  Full Article

Arsanis Posts Qtrly Loss Per Share $0.74
Thursday, 10 May 2018 

May 10 (Reuters) - Arsanis Inc ::ASN100 PHASE 2 TRIAL INTERIM ANALYSIS RESULTS EXPECTED IN LATE JUNE.QTRLY LOSS PER SHARE $0.74.AS OF MARCH 31, 2018, OUR CASH AND CASH EQUIVALENTS TOTALED $64.0 MILLION.  Full Article

Arsanis Inc - Out Licenses Preclinical Stage E. Coli Monoclonal Antibodies
Wednesday, 4 Apr 2018 

April 4 (Reuters) - Arsanis Inc ::LICENSES PRECLINICAL STAGE E. COLI MONOCLONAL ANTIBODIES.BB100 SECURED EXCLUSIVE,WORLDWIDE PRECLINICAL DEVELOPMENT LICENSE, OPTION TO DEVELOPMENT, COMMERCIALIZATION LICENSE, TO MABS TARGETING E. COLI.  Full Article

Arsanis Reports Q4 Net Loss $1.68 Per Share
Friday, 9 Mar 2018 

March 9 (Reuters) - Arsanis Inc ::ARSANIS REPORTS FINANCIAL RESULTS AND HIGHLIGHTS FOR FOURTH QUARTER AND FULL YEAR 2017.ARSANIS INC - FOR THE FOURTH QUARTER ENDED DECEMBER 31, 2017, ARSANIS REPORTED NET LOSS OF $1.68 LOSS PER SHARE.ARSANIS INC - AS OF DECEMBER 31, 2017, ARSANIS'S CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES AND INVESTMENTS TOTALED $76.8 MILLION.  Full Article

Arsanis Inc Files To Say It Has Raised $20 Million In Equity Financing - SEC Filing
Tuesday, 5 Dec 2017 

Dec 4 (Reuters) - Arsanis Inc ::ARSANIS INC FILES TO SAY IT HAS RAISED $20 MILLION IN EQUITY FINANCING - SEC FILING.  Full Article

OrbiMed Advisors Reports 13.07 Percent Stake In Arsanis As Of Nov 20 - SEC Filing ‍​
Friday, 1 Dec 2017 

Nov 30 (Reuters) - OrbiMed Advisors LLC::ORBIMED ADVISORS LLC REPORTS 13.07 PERCENT STAKE IN ARSANIS INC AS OF NOVEMBER 20 - SEC FILING ‍​.ORBIMED ADVISORS LLC - CAUSED OPI IV TO ACQUIRE COMMON STOCK OF THE ARSANIS INC FOR THE PURPOSE OF MAKING AN INVESTMENT.  Full Article

Terrance G. Mcguire Reports A 13.7 Percent Stake In Arsanis Inc As Of November 20, 2017 - SEC Filig
Thursday, 30 Nov 2017 

Nov 29 (Reuters) - Arsanis Inc ::TERRANCE G. MCGUIRE REPORTS A 13.7 PERCENT STAKE IN ARSANIS INC AS OF NOVEMBER 20, 2017 - SEC FILIG.  Full Article

New Enterprise Associates 16 L.P. Reports 14.6 Percent Stake In Arsanis As Of Nov 20
Thursday, 30 Nov 2017 

Nov 29 (Reuters) - NEW ENTERPRISE ASSOCIATES 16 L.P:NEW ENTERPRISE ASSOCIATES 16 L.P. REPORTS A 14.6 PERCENT STAKE IN ARSANIS AS OF NOVEMBER 20, 2017 - SEC FILING.  Full Article

Arsanis Inc shares debut about 30 pct above IPO price‍​
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - :Arsanis Inc shares open at $13.00 in debut on the NASDAQ versus IPO price of $10.00 per share‍​.  Full Article

Arsanis prices initial public offering of 4 mln common shares at $10 per share​
Thursday, 16 Nov 2017 

Nov 15 (Reuters) - Arsanis Inc -:Arsanis announces pricing of initial public offering.‍Announced pricing of initial public offering of 4,000,000 shares of common stock at public offering price of $10.00 per share​.  Full Article

BRIEF-Arsanis Posts Qtrly Loss Per Share $0.74

* ASN100 PHASE 2 TRIAL INTERIM ANALYSIS RESULTS EXPECTED IN LATE JUNE